PubRank

Nils Wilking

Author PubWeight™ 25.05‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401. J Clin Oncol 2006 2.89
2 [A model for structured introduction of new drugs. The aim is to offer all patients appropriate treatment]. Lakartidningen 2008 1.93
3 [Great risk of future problems for Swedish cancer care]. Lakartidningen 2010 1.92
4 A catalyst for change: the European cancer Patient's Bill of Rights. Oncologist 2014 1.55
5 Quality of life in women with breast cancer during the first year after random assignment to adjuvant treatment with marrow-supported high-dose chemotherapy with cyclophosphamide, thiotepa, and carboplatin or tailored therapy with Fluorouracil, epirubicin, and cyclophosphamide: Scandinavian Breast Group Study 9401. J Clin Oncol 2003 1.53
6 Basoluminal carcinoma: a new biologically and prognostically distinct entity between basal and luminal breast cancer. Clin Cancer Res 2006 1.38
7 Clinical experience with Zarzio® in Europe: what have we learned? Support Care Cancer 2013 1.30
8 Knowledge and understanding among cancer patients consenting to participate in clinical trials. Eur J Cancer 2008 1.28
9 Health related quality of life in different states of breast cancer. Qual Life Res 2007 1.24
10 Forecasting drug utilization and expenditure in a metropolitan health region. BMC Health Serv Res 2010 1.13
11 Levels of knowledge and perceived understanding among participants in cancer clinical trials - factors related to the informed consent procedure. Clin Trials 2010 1.12
12 Cost-effectiveness of HER2 testing and trastuzumab therapy for metastatic breast cancer. Acta Oncol 2008 1.07
13 Resource use and costs associated with different states of breast cancer. Int J Technol Assess Health Care 2007 1.00
14 Cost of breast cancer in Sweden in 2002. Eur J Health Econ 2007 0.96
15 The meaning of breast cancer. Acta Oncol 2003 0.91
16 A review of breast cancer care and outcomes in Latin America. Oncologist 2013 0.89
17 Cancer vaccines and immunotherapeutics: challenges for pricing, reimbursement and market access. Hum Vaccin Immunother 2012 0.87
18 Hormone replacement therapy after breast cancer: 10 year follow up of the Stockholm randomised trial. Eur J Cancer 2012 0.85
19 Cost-effectiveness of exemestane versus tamoxifen as adjuvant therapy for early-stage breast cancer after 2-3 years treatment with tamoxifen in Sweden. Breast Cancer Res Treat 2006 0.83
20 Trastuzumab use in breast cancer patients in the six Health Care Regions in Sweden. Acta Oncol 2010 0.78
21 Audio-recorded information to patients considering participation in cancer clinical trials - a randomized study. Acta Oncol 2014 0.75
22 Tailored chemotherapy doses based on toxicity in breast cancer result in similar quality of life values, irrespective of given dose levels. Acta Oncol 2011 0.75
23 [Pharmaceuticals can be cost-effective in the long run]. Lakartidningen 2010 0.75